Recent National Health and Nutrition Examination Surveys (NHANES) in the United States reveal an apparent decline in both awareness and treatment of hypertension, and also provide convincing evidence that we are failing to adequately control high blood pressure (BP) to current recommended treatment goal of BPs below 140/90 mm Hg. 1 The problem of hypertension control is not unique to the USA, and in fact, represents a worldwide problem. 2 While estimates suggest that approximately 25% of the world's adult population is hypertensive, only 12 to 13% are controlled to recommended treatment goals.
There are numerous factors to be considered when addressing ineffective hypertension control. 3 One obvious problem is patient adherence with medication. Many patients are adverse to taking medication for BP control, and when prescribed medication, are prone to discontinue that medication within several months to 1 year. Reasons for patients' non-adherence include a failure to understand the treatment goals and potential benefits of effective therapy. In this respect, providers may be partly responsible for inadequate patient-provider communication. If patients do not clearly understand the long-term benefits of treating hypertension, the likelihood of optimal compliance is poor for a disease that often has no apparent symptoms. Patients' complaints of adverse effects from medications, whether subjective or objective, also represent a major barrier, and one of the most commonly cited reasons for discontinuing medication. This too may result from a failure on the part of the provider to educate the patient about the prescribed medication, to discuss the likelihood and character of side effects, and to encourage patients to call with treatment concerns before discontinuing therapy. Evidence also shows that compliance is improved with regular and more frequent BP follow-up which can often be provided by non-physician personnel in the office setting.
Physician behaviour also represents a major obstacle to the successful achievement of target BP goals. Physicians may disagree with consensus guidelines, and that is fine as long as they determine appropriate alternate treatment approaches. A greater concern is the recalcitrance of physicians prescribing of the older antihypertensive agents, the diuretics and adrenergic blockers. Expressed concerns relative to effects on other comorbid conditions such as dyslipidaemia, and carbohydrate intolerance, or electrolyte abnormalities, while appropriate, are not supported by current data. The benefits of using these agents in currently recommended doses far outweigh any prior reports of adverse biochemical effects.
The major concern with hypertension management relates to the reluctance of physicians to change treatment when BP control is inadequate. Therapeutic reluctance is evident from the standpoint of both appropriate dosing of antihypertensive drugs and also efforts to control BP with monotherapy as opposed to combination therapy. The majority of physicians practice sequential monotherapy in an effort to identify a single drug preparation that will normalise BP. Available evidence with today's antihypertensive drugs suggests that upwards of 30 to 60% of patients will be controlled with a single drug preparation, while two drugs in combination are likely to improve control rates to 80 to 85%; three or more drugs will provide control in upwards of 90 to 95% of patients with essential hypertension. 4 These data are generated from clinical trials such as the V.A. Cooperative Study, which has also addressed the issue of sequential monotherapy. In no case did the second drug added provide better response rates than the initial drug used in patient groups. Thus, reliance on single-drug therapy, regardless of dosage, guarantees failure in the control of a majority of any clinician's hypertensive patient population.
The Evaluation and Interventions for Systolic BP Elevation: Regional and Global (EISBERG) project gathered data from extensive self-reporting diaries and questionnaires which were completed by both general physicians and cardiovascular specialists on approximately 17 000 patients from seven countries. 5 The project investigated both the quantitative and qualitative aspects of current treatment of hypertension internationally. The quantitative study indicated major shortcomings in BP control, and in particular, poor control of elevated systolic pressure, which accounted for 90% of treatment failures. The qualitative research was based upon semi-structured interviews with professionals, patients and their care-givers, and indicated that there were misconceptions among physicians regarding the relative importance of systolic and diastolic BP, the need for more aggressive treatment in the elderly, and the need for improved physician-patient interaction.
What have we learned from recent clinical trials?
Several recent clinical trials have focused on three major areas of hypertension therapy: (1) the benefits of more aggressive lowering of BP vs higher BPs; (2) the efficacy of newer classes of drugs vs standard therapy with diuretics and/or beta-blockers; and (3) does lower BP reduce morbidity and mortality regardless of the agent used?
The Hypertension Optimal Treatment (HOT) trial was a forced titration study of more than 18 000 patients who received a calcium antagonist-based treatment regimen, randomised to target diastolic BP (DBP) Ͻ90, 85, or 80 mm Hg. 6 A primary goal of the study was to determine if a lower achieved DBP was associated with further reduction in cardiovascular events. Unfortunately, the distribution of DBP from 6-month's follow-up to end of the study at 4.5 years was not sufficient to demonstrate a significant difference in major cardiovascular events or cardiovascular mortality for the entire treatment group. However, a subgroup of 1500 patients with type II diabetes mellitus clearly derived benefit in those patients treated to a DBP of Ͻ80 mm Hg compared with those treated to a traditional DBP treatment goal of Ͻ90 mm Hg. Optimal reduction in cardiovascular events was obtained at a systolic BP (SBP) of 139 mm Hg and DBP of 83 mm Hg. Further reductions to as low as a SBP of 120 and DBP 70 mm Hg were not associated with any apparent increase in coronary events.
There were several other important findings from the HOT study that deserve mention. With sufficient Journal of Human Hypertension effort and predefined goal BPs more than 90% of patients in the study achieved and maintained a DBP Ͻ90 mm Hg, and 57% were treated to a DBP Ͻ80 mm Hg. A sub-study of the HOT trial in 922 hypertensive patients assessed the effects of aggressive BP lowering on quality of life. The lower the achieved DBP, the greater the improvement in sense of well-being. The study also demonstrated the importance of combination therapy needed to achieve target BPs. Overall, 60% of patients were on monotherapy at baseline with a mean BP of 161/98 mm Hg. At the end of the study, 70% were receiving combination therapy to a mean achieved BP of 142/93 mm Hg. An increased requirement of combination therapy was also observed in the three DBP treatment groups.
The United Kingdom Prospective Diabetes Study (UKPDS) group showed that during tighter control of BP (144/82 mm Hg) compared to less tight control (154/87 mm Hg) in type II diabetics was associated with fewer myocardial infarctions, strokes, microvascular disease, and fewer diabetic-related deaths. 7 The Antihypertensive and Lipid-Lowering to Reduce Heart Attack trial (ALLHAT) compares three newer agents, amlodipine, doxazosin, and lisinopril to chlorthalidone in more than 42 000 older patients with essential hypertension. 8 The study was designed to maximise recruitment of African Americans and patients with type II diabetes mellitus. The goal of therapy during the study is to achieve and maintain a BP Ͻ140/90 mm Hg. After 3 years of follow-up 59% of patients were, in fact, maintaining a BP below goal. After 3.3 years of median followup, the doxazosin arm of the study was discontinued because of an observed relative risk of congestive heart failure with this medication that was twice that observed with chlorthalidone. The lesson learned so far in this trial is that, for some drugs, BP lowering is an inadequate marker for the health benefits of a particular drug. Comparative outcome trials such as ALLHAT are essential for documenting optimal drug benefit to risk balance, and for guiding the selection of antihypertensive medications.
The Captopril Primary Prevention Project (CAPPP) compared the ACE inhibitor, captopril, to standard therapy with diuretic or beta-blocker in 10 985 hypertensive patients. 9 The primary end points were fatal and non-fatal myocardial infarction, stroke, and other cardiovascular events. In a similar trial, the STOP Hypertension II trial, compared both an ACE inhibitor and a calcium antagonist to conventional therapy in approximately 6600 patients. 10 These two studies demonstrated no significant differences in benefit or primary end points from treatment with an ACE inhibitor, a calcium antagonist, or standard diuretic/beta-blocker therapy.
Two most recent clinical trial reports assessed the efficacy of calcium antagonists to lower BP and influence cardiovascular outcomes such as heart attack and stroke. The Nordic diltiazem (NORDIL) study compared effectiveness of diltiazem with that of diuretics, beta-blockers or both on cardiovascular risk and mortality on a study population of 10 881 patients aged 50 to 74 years. Diltiazem proved to be as effective as diuretic/beta-blocker treatment in preventing the combined primary end point of allstrokes, myocardial infarction, and other cardiovascular deaths. Diltiazem was, however, significantly more effective in lowering the rate of all strokes, while fatal and non-fatal myocardial infarction rates tended to favour treatment with diuretics or beta-blockers.
In the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT), 6321 patients aged 55 to 80 years with hypertension and at least one additional risk factor were randomised to nifedipine GITS or hydrochlorothiazide/amiloride. 11 The primary outcome of this study was all cardiovascular deaths, myocardial infarction, heart failure, or stroke. BP reduction was identical and at the end of the study, nifedipine once daily and hydrochlorothiazide/amiloride were equally effective in preventing overall cardiovascular or cerebrovascular complications.
Finally, van den Hoogen and colleagues reported six different population groups in which the relative increase in long-term mortality attributable to coronary heart disease for a given increase in BP is quite similar, whereas the absolute risk at the same BP level varies substantially. 12 In this study, sustained differences of 10 mm Hg in SBP and of 5 mm Hg in DBP were each associated with a 28% difference in the risk of death from coronary heart disease. This linear relationship due to coronary heart disease was observed irrespective of whether hypertension was present or not. However, among the different populations, the absolute risk of death varied by a factor of 3-4 from 44 deaths/10 000 person-years in Japan and Mediterranean southern Europe to 153 deaths/10 000 person-years in northern Europe.
These findings by van den Hoogen et al would suggest that the benefits of blood pressure reduction are not restricted to hypertensive persons alone, and offer rationale that many patients at high risk for major cardiovascular events may benefit from a substantial reduction in BP. At the same time, the highly variable absolute risk of death likely depends on factors other than blood pressure such as gender, age, target organ damage, and other risk factors. These implications will have a significant bearing on the treatment of cardiovascular disease in different parts of the world.
Summary
In conclusion, evidence from recent clinical trials has provided both new evidence as well as support of current observations relative to more aggressive treatment of hypertension.
(1) Combination therapy will be required to achieve and maintain lower BP goals.
(2) Recent studies have shown the added benefits of treating to even lower BP vs more traditional BP levels.
(3) Aggressive treatment of the diabetic hypertensive patient offers risk reduction exceeding that observed in the non-diabetic population.
(4) ACE inhibitors and calcium antagonists provide risk reductions similar to older diuretics and beta-adrenergic blockers.
(5) BP reduction to the same degree with different classes of agents does not necessarily provide the same risk benefits.
(6) The potential benefits of BP reduction are not restricted to those individuals with hypertension based on current classification of BP.
